Therefore, BPF has potential as a therapeutic drug for CML as well as for various types of cancer cells mediated by aberrant activation of MEK-ERK pathway. The gene discussed is MAP2K7; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.